{"id":901481,"date":"2026-06-29T19:52:23","date_gmt":"2026-06-29T19:52:23","guid":{"rendered":"https:\/\/www.europesays.com\/us\/901481\/"},"modified":"2026-06-29T19:52:23","modified_gmt":"2026-06-29T19:52:23","slug":"heart-kidney-prescription-medications-recalled-nbc-chicago","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/us\/901481\/","title":{"rendered":"Heart, kidney prescription medications recalled \u2013 NBC Chicago"},"content":{"rendered":"<p>Nearly one million bottles of common heart and kidney prescription medication have been voluntarily recalled due to &#8220;presence of a foreign substance,&#8221; according to a Food and Drug enforcement report. <\/p>\n<p>The recall was issued by California drugmaker Amgen June 4, the report said. In total, more than 944,000 bottles were recalled, with the prescription pills distributed to patients nationwide. <\/p>\n<p>One of the medications recalled was Coloranor (generic name ivabradine), the report said, with 5 mg tablets and a number of lots impacted. Expiration dates range from Aug. 2026 to Dec. 2028. The other drug was Sensipar (generic name cinacalcet), with 30 mg tablets recalled. <\/p>\n<p>Sensipar was recalled, the report said, due to deviations during the manufacturing process, which could impact the safety and effectiveness of the pills. <\/p>\n<p><a href=\"https:\/\/hfsa.org\/fda-approves-corlanorr-ivabradine\" data-type=\"link\" data-id=\"https:\/\/hfsa.org\/fda-approves-corlanorr-ivabradine\" rel=\"nofollow noopener\" target=\"_blank\">According to Amgen<\/a>, Colanor is used to treat heart failure. The drug was approved by the FDA in 2015. Sensipar is typically used to treat chronic kidney disease.  <\/p>\n<p>The recall comes amid other recent drug and medication recalls, including recalls involving blood pressure and anxiety prescriptions. <\/p>\n<p>NBC Chicago reached out to Amgen for comment on this story. <\/p>\n","protected":false},"excerpt":{"rendered":"Nearly one million bottles of common heart and kidney prescription medication have been voluntarily recalled due to &#8220;presence&hellip;\n","protected":false},"author":3,"featured_media":901482,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[34],"tags":[210,1060,12310,67,132,68],"class_list":["post-901481","post","type-post","status-publish","format-standard","has-post-thumbnail","category-medication","tag-health","tag-medication","tag-recalls","tag-united-states","tag-unitedstates","tag-us"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@us\/116835145978797411","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/901481","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/comments?post=901481"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/901481\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media\/901482"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media?parent=901481"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/categories?post=901481"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/tags?post=901481"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}